Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients

Curr Infect Dis Rep. 2011 Feb;13(1):1-3. doi: 10.1007/s11908-010-0148-6.
No abstract available